HCPCS code J9049: Bortezomib injection, hospira product, per 0.1 mg2026 Medicare rate & RVUs in Oregon
J9049 identifies the Hospira bortezomib product administered in cancer treatment regimens, with each HCPCS unit representing 0.1 mg of drug.
CMS doesn’t publish an office rate for J9049 in Oregon.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9049 covers
J9049 identifies bortezomib supplied as the Hospira product, which is distinguished from the product represented by J9041 as not therapeutically equivalent. Bortezomib is an antineoplastic drug used in treatment regimens for multiple myeloma and mantle cell lymphoma. Oncology clinicians administer it by subcutaneous injection or intravenously in clinic or hospital settings. The drug code reports the quantity administered; the administration service is reported separately when separately billable.
CMS assigns status E, excluding J9049 from the physician fee schedule. It is a Part B drug, and when Medicare covers it, payment generally comes through CMS quarterly Average Sales Price drug pricing files under another payment method. CMS leaves coverage to the Medicare contractor’s judgment. Each unit represents 0.1 mg, so report the administered amount in multiples of 0.1 mg.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9049 pays more and less in Oregon
| Payment locality | Office | Facility |
|---|---|---|
| Portland, OR | Unavailable | Unavailable |
| Rest of Oregon | Unavailable | Unavailable |
How the J9049 rate is calculated
Each of J9049’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9049
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9049
J9049 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9049
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9049 isn’t priced in this setting.
J9049 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9041Bortezomib injectionPer 0.1 mg
- J9049 identifies the Hospira bortezomib product and is designated as not therapeutically equivalent to J9041. Use the code matching the product administered.
- J9046Bortezomib injectionDr. Reddy's, per 0.1 mg
- J9046 identifies the Dr. Reddy’s bortezomib product; J9049 identifies the Hospira product. The manufacturer-specific product determines which code applies.
- J9048Bortezomib injectionFresenius Kabi, per 0.1 mg
- J9048 identifies the Fresenius Kabi bortezomib product, while J9049 identifies the Hospira product. Choose based on the product administered.
J9049 billing questions
When should J9049 be used instead of J9041?
Use J9049 for the Hospira bortezomib product. The code identifies a product that is not therapeutically equivalent to the product represented by J9041; select the code that matches the product administered.
How many units should be reported?
Each unit represents 0.1 mg. Divide the administered dose in milligrams by 0.1 to determine the number of units.
Does J9049 include drug administration?
No. J9049 reports the bortezomib quantity, not the injection or infusion service; report administration separately when it is separately billable.
How does Medicare treat J9049?
CMS assigns status E, excluding the code from the physician fee schedule. When Medicare covers the Part B drug, payment generally uses CMS quarterly ASP drug pricing files, and coverage is left to the Medicare contractor’s judgment.
Is J9049 reported for every bortezomib product?
No. J9049 identifies the Hospira product. Other bortezomib products have distinct HCPCS codes, so use the code corresponding to the product administered.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9049 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist